Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs TeraWulf Inc (WULF) Price & Performance

Merck & Co., Inc.Trade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs TeraWulf Inc — how do they compare? Merck & Co., Inc. trades at $132.81 (market cap $321.77B), while TeraWulf Inc trades at $17.04 (market cap $8.35B). The key difference: Merck & Co., Inc. is far larger — about 38.5× TeraWulf Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.

MRKWULF
Market Cap
$321.77B$8.35B
Sector
HealthTechnology
52-Week High
$131.84$28.98
52-Week Low
$77.60$5.24
Enterprise Value
$368.53B$10.97B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

TeraWulf Inc

WULF stock trades at $17.69, up 9.2% on the day amid a broader rally in AI infrastructure stocks. The technical picture is bearish with key support at $16 and resistance at $18. Fundamentally, the company reported a Q2 2026 net loss of $1.94 per share, missing estimates, while revenue trends are stable. Despite negative profitability metrics, analyst sentiment remains unanimously bullish with a $38.00 consensus price target, driven by expansion in high-performance computing capacity.

The outlook hinges on execution of its HPC growth strategy, but significant risks include persistent losses, high capital expenditure, and exposure to regulatory shifts. The stock offers high upside if operational targets are met, yet carries substantial volatility and execution risk for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF